Biontech set a date for a joint launch of a vaccine with Pfizer

Biontech said today, Thursday, that it is possible to launch a joint vaccine with Pfizer in December.

And apparently only a few days separate the Pfizer vaccine, whose clinical trials have proven to be highly successful, from the millions waiting for it. Pfizer and Bayontek announced in a joint statement Wednesday that they would apply for a license from the US Food and Drug Administration to commercialize the vaccine “within days.”
It also confirmed that its joint vaccine to prevent COVID-19 is 95% effective based on the complete results of a large-scale clinical trial.

The partial results of this trial, which were published last week, showed the effectiveness of “more than 90%.”

In the details of the experiments conducted by the two companies, 162 members of a group that received a placebo vaccine were infected with Covid-19, compared with just eight members of the group that received the actual vaccine.

It is noteworthy that the two companies announced early last week that the vaccine has proven to be “90% effective” after a preliminary analysis of the results of the third phase of clinical trials, which is the last before submitting the license application.

They also explained that protection against coronavirus is achieved at a high rate within 28 days of taking the first dose, and that it is completed only one week after the second dose.

Heat obstacle
However, obstacles had previously been raised, regarding the issue of its distribution, related to the need to preserve this vaccine at very low temperatures. British Health Minister Matt Hancock revealed, for example, a few days ago that a very important problem stands in the way of transporting the two Pfizer / Bionic vaccines from the place of manufacture to the individuals who will receive it, since the vaccine It must be kept at a temperature of 70 degrees below zero, and cannot be placed. At higher temperatures, more than four times during this flight.

This issue represents a great challenge for many countries, given that most of the known vaccines do not require low temperature and, therefore, most hospitals do not have an infrastructure that allows them to cope with this new vaccine.